Extended-release naltrexone plus medical management alcohol treatment in primary care: Findings at 15 months

Joshua D. Lee, Ellie Grossman, Laura Huben, Marc Manseau, Jennifer McNeely, John Rotrosen, David Stevens, Marc N. Gourevitch

Research output: Contribution to journalArticlepeer-review


The feasibility of long-term extended-release naltrexone (XR-NTX) alcohol treatment is unknown. Following an initial 12-week, single-arm, observational trial of XR-NTX plus medical management (MM) in primary care, we offered 48 additional weeks of XR-NTX treatment (12 additional monthly injections) in two public primary care clinics as a naturalistic extension study. Of 65 alcohol dependent adults initiating XR-NTX treatment, 40 (62%) completed the initial 12-week XR-NTX observational trial, and 19 (29%) continued treatment for a median of 38. weeks total (range, 16-72. weeks; median 8 total XR-NTX injections). Among active extension phase participants, self-reported rates of drinking days (vs. last 30 days pre-treatment baseline) were low: median 0.2 vs. 6.0. drinks per day; 82 vs. 38% days abstinent; 11 vs. 61% heavy drinking days. Long-term XR-NTX treatment in a primary care MM model was feasible and may promote lasting drinking reductions or alcohol abstinence (clinical trial: NCT00620750).

Original languageEnglish (US)
Pages (from-to)458-462
Number of pages5
JournalJournal of Substance Abuse Treatment
Issue number4
StatePublished - Dec 2012


  • Alcohol medical management
  • Alcohol pharmacotherapy
  • Alcohol treatment
  • Extended-release naltrexone
  • Primary care

ASJC Scopus subject areas

  • Phychiatric Mental Health
  • Medicine (miscellaneous)
  • Clinical Psychology
  • Psychiatry and Mental health


Dive into the research topics of 'Extended-release naltrexone plus medical management alcohol treatment in primary care: Findings at 15 months'. Together they form a unique fingerprint.

Cite this